Volume 17, Issue 1 p. 25-32

Melatonin modulates growth factor activity in MCF-7 human breast cancer cells

Samuel Cos

Samuel Cos

Department of Physiology and Pharmacology College of Medicine, University of Cantabria, Santander, Spain

Search for more papers by this author
David E. Blask

Corresponding Author

David E. Blask

The Mary Imogene Bassett Hospital, Research Institute, Cooperstown, NY, U.S.A.

Address reprint requests to David E. Blask, Ph. D., M. D., The Mary Imogene Bassett Hospital, Research Institute, Cooperstown, NY 13326-1394, U.S.A.Search for more papers by this author
First published: August 1994
Citations: 56

Abstract

Cos S, Blask DE. Melatonin modulates growth factor activity in MCF-7 human breast cancer cells. J. Pineal Res. 1994: 17: 25–32.

Melatonin has been shown to have direct oncostatic actions on estrogen-responsive, MCF-7 human breast cancer cells in culture. In the present study, we examined whether these inhibitory actions on cell growth may be mediated through actions on bioassayable growth factor activity. In order to test this hypothesis, we estimated the growth factor activity of conditioned medium (CM) from estradiol (E2), or melatonin-treated cells, in the presence or absence of melatonin on MCF-7 cell growth. We also determined whether melatonin inhibits the action of epidermal growth factor (EGF) action in the absence of E2. The addition of melatonin (10-9 M) to the cultures of MCF-7 cells with CM from E2 (10-8 M)-treated cells significantly inhibited the growth stimulatory activity of CM, suggesting that melatonin inhibited cell proliferation by blocking the action of E2-induced autocrine growth stimulatory factors. Conditioned medium from melatonin-treated cells significantly inhibited cell proliferation, while an additional supply of melatonin to these cultures had an even greater inhibitory effect. Melatonin was also active in the complete absence of serum as long as cell growth was stimulated by EGF, an E2-inducible growth factor. The inhibitory effect of melatonin increased as the dose of EGF increased. This non-antiestrogenic inhibitory effect of melatonin was reversed by E2, but not by EGF itself, suggesting that melatonin requires accessible estrogen receptor sites for its inhibitory activity on the growth stimulating action of EGF. Taken together, these findings suggest that melatonin may inhibit the action and/or release of growth stimulatory factors as well as stimulate the release of growth inhibitory factors in culture. Furthermore, these findings indicate an important interaction of melatonin with E2-inducible autocrine growth factors such as EGF in the inhibition of MCF-7 cell growth.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.